Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

A central role for glial CCR5 in directing the neuropathological interactions of HIV-1 Tat and opiates.

Kim S, Hahn YK, Podhaizer EM, McLane VD, Zou S, Hauser KF, Knapp PE.

J Neuroinflammation. 2018 Oct 10;15(1):285. doi: 10.1186/s12974-018-1320-4.

2.

Differential Tolerance to FTY720-Induced Antinociception in Acute Thermal and Nerve Injury Mouse Pain Models: Role of Sphingosine-1-Phosphate Receptor Adaptation.

Sim-Selley LJ, Wilkerson JL, Burston JJ, Hauser KF, McLane V, Welch SP, Lichtman AH, Selley DE.

J Pharmacol Exp Ther. 2018 Sep;366(3):509-518. doi: 10.1124/jpet.118.248260. Epub 2018 Jun 26.

PMID:
29945931
3.

Reduced intraepidermal nerve fibre density, glial activation, and sensory changes in HIV type-1 Tat-expressing female mice: involvement of Tat during early stages of HIV-associated painful sensory neuropathy.

Wodarski R, Bagdas D, Paris JJ, Pheby T, Toma W, Xu R, Damaj MI, Knapp PE, Rice ASC, Hauser KF.

Pain Rep. 2018 May 14;3(3):e654. doi: 10.1097/PR9.0000000000000654. eCollection 2018 May.

4.

Opiate Drugs with Abuse Liability Hijack the Endogenous Opioid System to Disrupt Neuronal and Glial Maturation in the Central Nervous System.

Hauser KF, Knapp PE.

Front Pediatr. 2018 Jan 23;5:294. doi: 10.3389/fped.2017.00294. eCollection 2017. Review.

5.

Characterization of cell-cell junction changes associated with the formation of a strong endothelial barrier.

McRae M, LaFratta LM, Nguyen BM, Paris JJ, Hauser KF, Conway DE.

Tissue Barriers. 2018 Jan 2;6(1):e1405774. doi: 10.1080/21688370.2017.1405774. Epub 2018 Feb 1.

PMID:
29388870
6.

CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward.

Gonek M, McLane VD, Stevens DL, Lippold K, Akbarali HI, Knapp PE, Dewey WL, Hauser KF, Paris JJ.

Brain Behav Immun. 2018 Mar;69:124-138. doi: 10.1016/j.bbi.2017.11.006. Epub 2017 Nov 13.

PMID:
29146238
7.

Effects of HIV-1 Tat and Methamphetamine on Blood-Brain Barrier Integrity and Function In Vitro.

Patel S, Leibrand CR, Palasuberniam P, Couraud PO, Weksler B, Jahr FM, McClay JL, Hauser KF, McRae M.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01307-17. doi: 10.1128/AAC.01307-17. Print 2017 Dec.

8.

Chronic low-level expression of HIV-1 Tat promotes a neurodegenerative phenotype with aging.

Dickens AM, Yoo SW, Chin AC, Xu J, Johnson TP, Trout AL, Hauser KF, Haughey NJ.

Sci Rep. 2017 Aug 10;7(1):7748. doi: 10.1038/s41598-017-07570-5.

9.

Selective Vulnerability of Striatal D2 versus D1 Dopamine Receptor-Expressing Medium Spiny Neurons in HIV-1 Tat Transgenic Male Mice.

Schier CJ, Marks WD, Paris JJ, Barbour AJ, McLane VD, Maragos WF, McQuiston AR, Knapp PE, Hauser KF.

J Neurosci. 2017 Jun 7;37(23):5758-5769. doi: 10.1523/JNEUROSCI.0622-17.2017. Epub 2017 May 4.

10.

Connexin-purinergic signaling in enteric glia mediates the prolonged effect of morphine on constipation.

Bhave S, Gade A, Kang M, Hauser KF, Dewey WL, Akbarali HI.

FASEB J. 2017 Jun;31(6):2649-2660. doi: 10.1096/fj.201601068R. Epub 2017 Mar 9.

11.

Productive infection of human neural progenitor cells by R5 tropic HIV-1: opiate co-exposure heightens infectivity and functional vulnerability.

Balinang JM, Masvekar RR, Hauser KF, Knapp PE.

AIDS. 2017 Mar 27;31(6):753-764. doi: 10.1097/QAD.0000000000001398.

12.

HIV-1 Tat disrupts blood-brain barrier integrity and increases phagocytic perivascular macrophages and microglia in the dorsal striatum of transgenic mice.

Leibrand CR, Paris JJ, Ghandour MS, Knapp PE, Kim WK, Hauser KF, McRae M.

Neurosci Lett. 2017 Feb 15;640:136-143. doi: 10.1016/j.neulet.2016.12.073. Epub 2017 Jan 3.

13.

Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.

Arnatt CK, Falls BA, Yuan Y, Raborg TJ, Masvekar RR, El-Hage N, Selley DE, Nicola AV, Knapp PE, Hauser KF, Zhang Y.

Bioorg Med Chem. 2016 Nov 15;24(22):5969-5987. doi: 10.1016/j.bmc.2016.09.059. Epub 2016 Sep 26.

14.

HIV-1 Tat exacerbates lipopolysaccharide-induced cytokine release via TLR4 signaling in the enteric nervous system.

Guedia J, Brun P, Bhave S, Fitting S, Kang M, Dewey WL, Hauser KF, Akbarali HI.

Sci Rep. 2016 Aug 5;6:31203. doi: 10.1038/srep31203.

15.

HIV-1 Tat causes cognitive deficits and selective loss of parvalbumin, somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron subpopulations.

Marks WD, Paris JJ, Schier CJ, Denton MD, Fitting S, McQuiston AR, Knapp PE, Hauser KF.

J Neurovirol. 2016 Dec;22(6):747-762. Epub 2016 May 13.

16.

Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrain.

Hahn YK, Paris JJ, Lichtman AH, Hauser KF, Sim-Selley LJ, Selley DE, Knapp PE.

Neurobiol Dis. 2016 Aug;92(Pt B):124-36. doi: 10.1016/j.nbd.2016.01.014. Epub 2016 Feb 1.

17.

5α-reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 Tat.

Paris JJ, Zou S, Hahn YK, Knapp PE, Hauser KF.

Brain Behav Immun. 2016 Jul;55:202-214. doi: 10.1016/j.bbi.2016.01.007. Epub 2016 Jan 13.

18.

Morphine Tolerance and Physical Dependence Are Altered in Conditional HIV-1 Tat Transgenic Mice.

Fitting S, Stevens DL, Khan FA, Scoggins KL, Enga RM, Beardsley PM, Knapp PE, Dewey WL, Hauser KF.

J Pharmacol Exp Ther. 2016 Jan;356(1):96-105. doi: 10.1124/jpet.115.226407. Epub 2015 Nov 5.

19.

HIV-1-Tat Protein Inhibits SC35-mediated Tau Exon 10 Inclusion through Up-regulation of DYRK1A Kinase.

Kadri F, Pacifici M, Wilk A, Parker-Struckhoff A, Del Valle L, Hauser KF, Knapp PE, Parsons C, Jeansonne D, Lassak A, Peruzzi F.

J Biol Chem. 2015 Dec 25;290(52):30931-46. doi: 10.1074/jbc.M115.675751. Epub 2015 Nov 3.

20.

Oligodendrocytes Are Targets of HIV-1 Tat: NMDA and AMPA Receptor-Mediated Effects on Survival and Development.

Zou S, Fuss B, Fitting S, Hahn YK, Hauser KF, Knapp PE.

J Neurosci. 2015 Aug 12;35(32):11384-98. doi: 10.1523/JNEUROSCI.4740-14.2015.

21.

Cocaine promotes both initiation and elongation phase of HIV-1 transcription by activating NF-κB and MSK1 and inducing selective epigenetic modifications at HIV-1 LTR.

Sahu G, Farley K, El-Hage N, Aiamkitsumrit B, Fassnacht R, Kashanchi F, Ochem A, Simon GL, Karn J, Hauser KF, Tyagi M.

Virology. 2015 Sep;483:185-202. doi: 10.1016/j.virol.2015.03.036. Epub 2015 May 15.

22.

Plasma membrane poration by opioid neuropeptides: a possible mechanism of pathological signal transduction.

Maximyuk O, Khmyz V, Lindskog CJ, Vukojević V, Ivanova T, Bazov I, Hauser KF, Bakalkin G, Krishtal O.

Cell Death Dis. 2015 Mar 12;6:e1683. doi: 10.1038/cddis.2015.39.

23.

Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca²⁺]i, oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity.

Fitting S, Zou S, El-Hage N, Suzuki M, Paris JJ, Schier CJ, Rodríguez JW, Rodriguez M, Knapp PE, Hauser KF.

Curr HIV Res. 2014;12(6):424-34.

24.

Chronic HIV-1 Tat and HIV reduce Rbfox3/NeuN: evidence for sex-related effects.

Hahn YK, Masvekar RR, Xu R, Hauser KF, Knapp PE.

Curr HIV Res. 2015;13(1):10-20.

25.

Sensitization of enteric neurons to morphine by HIV-1 Tat protein.

Fitting S, Ngwainmbi J, Kang M, Khan FA, Stevens DL, Dewey WL, Knapp PE, Hauser KF, Akbarali HI.

Neurogastroenterol Motil. 2015 Apr;27(4):468-80. doi: 10.1111/nmo.12514. Epub 2015 Feb 19.

26.

RelB/p50 complexes regulate cytokine-induced YKL-40 expression.

Bhardwaj R, Yester JW, Singh SK, Biswas DD, Surace MJ, Waters MR, Hauser KF, Yao Z, Boyce BF, Kordula T.

J Immunol. 2015 Mar 15;194(6):2862-70. doi: 10.4049/jimmunol.1400874. Epub 2015 Feb 13.

27.

GSK3β-activation is a point of convergence for HIV-1 and opiate-mediated interactive neurotoxicity.

Masvekar RR, El-Hage N, Hauser KF, Knapp PE.

Mol Cell Neurosci. 2015 Mar;65:11-20. doi: 10.1016/j.mcn.2015.01.001. Epub 2015 Jan 20.

28.

The effects of human immunodeficiency virus infection on the expression of the drug efflux proteins P-glycoprotein and breast cancer resistance protein in a human intestine model.

Ellis K, Marlin JW, Taylor TA, Fitting S, Hauser KF, Rice G, McRae M.

J Pharm Pharmacol. 2015 Feb;67(2):178-88. doi: 10.1111/jphp.12329. Epub 2014 Dec 31.

29.

Effects of HIV-1 Tat on enteric neuropathogenesis.

Ngwainmbi J, De DD, Smith TH, El-Hage N, Fitting S, Kang M, Dewey WL, Hauser KF, Akbarali HI.

J Neurosci. 2014 Oct 22;34(43):14243-51. doi: 10.1523/JNEUROSCI.2283-14.2014.

30.

Interactive HIV-1 Tat and morphine-induced synaptodendritic injury is triggered through focal disruptions in Na⁺ influx, mitochondrial instability, and Ca²⁺ overload.

Fitting S, Knapp PE, Zou S, Marks WD, Bowers MS, Akbarali HI, Hauser KF.

J Neurosci. 2014 Sep 17;34(38):12850-64. doi: 10.1523/JNEUROSCI.5351-13.2014.

31.

Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.

Hauser KF, Knapp PE.

Int Rev Neurobiol. 2014;118:231-313. doi: 10.1016/B978-0-12-801284-0.00009-9. Review.

32.

Morphine enhances HIV-1SF162-mediated neuron death and delays recovery of injured neurites.

Masvekar RR, El-Hage N, Hauser KF, Knapp PE.

PLoS One. 2014 Jun 20;9(6):e100196. doi: 10.1371/journal.pone.0100196. eCollection 2014.

33.

Rat nucleus accumbens core astrocytes modulate reward and the motivation to self-administer ethanol after abstinence.

Bull C, Freitas KC, Zou S, Poland RS, Syed WA, Urban DJ, Minter SC, Shelton KL, Hauser KF, Negus SS, Knapp PE, Bowers MS.

Neuropsychopharmacology. 2014 Nov;39(12):2835-45. doi: 10.1038/npp.2014.135. Epub 2014 Jun 6.

34.

Ibudilast (AV411), and its AV1013 analog, reduce HIV-1 replication and neuronal death induced by HIV-1 and morphine.

El-Hage N, Rodriguez M, Podhaizer EM, Zou S, Dever SM, Snider SE, Knapp PE, Beardsley PM, Hauser KF.

AIDS. 2014 Jun 19;28(10):1409-19. doi: 10.1097/QAD.0000000000000291.

35.

Glial modulators as potential treatments of psychostimulant abuse.

Beardsley PM, Hauser KF.

Adv Pharmacol. 2014;69:1-69. doi: 10.1016/B978-0-12-420118-7.00001-9. Review.

36.

Differential expression of the alternatively spliced OPRM1 isoform μ-opioid receptor-1K in HIV-infected individuals.

Dever SM, Costin BN, Xu R, El-Hage N, Balinang J, Samoshkin A, O'Brien MA, McRae M, Diatchenko L, Knapp PE, Hauser KF.

AIDS. 2014 Jan 2;28(1):19-30. doi: 10.1097/QAD.0000000000000113.

37.

Effects of chronic HIV-1 Tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and behavior.

Hahn YK, Podhaizer EM, Farris SP, Miles MF, Hauser KF, Knapp PE.

Brain Struct Funct. 2015 Mar;220(2):605-23. doi: 10.1007/s00429-013-0676-6. Epub 2013 Dec 19.

38.

Ligand-gated purinergic receptors regulate HIV-1 Tat and morphine related neurotoxicity in primary mouse striatal neuron-glia co-cultures.

Sorrell ME, Hauser KF.

J Neuroimmune Pharmacol. 2014 Mar;9(2):233-44. doi: 10.1007/s11481-013-9507-z. Epub 2013 Oct 25.

39.

Asymmetry of the endogenous opioid system in the human anterior cingulate: a putative molecular basis for lateralization of emotions and pain.

Watanabe H, Fitting S, Hussain MZ, Kononenko O, Iatsyshyna A, Yoshitake T, Kehr J, Alkass K, Druid H, Wadensten H, Andren PE, Nylander I, Wedell DH, Krishtal O, Hauser KF, Nyberg F, Karpyak VM, Yakovleva T, Bakalkin G.

Cereb Cortex. 2015 Jan;25(1):97-108. doi: 10.1093/cercor/bht204. Epub 2013 Aug 19.

40.

A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.

El-Hage N, Dever SM, Podhaizer EM, Arnatt CK, Zhang Y, Hauser KF.

AIDS. 2013 Sep 10;27(14):2181-90. doi: 10.1097/QAD.0b013e3283639804.

41.

A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities.

Yuan Y, Arnatt CK, El-Hage N, Dever SM, Jacob JC, Selley DE, Hauser KF, Zhang Y.

Medchemcomm. 2013 May 1;4(5):847-851.

42.

Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice.

Fitting S, Ignatowska-Jankowska BM, Bull C, Skoff RP, Lichtman AH, Wise LE, Fox MA, Su J, Medina AE, Krahe TE, Knapp PE, Guido W, Hauser KF.

Biol Psychiatry. 2013 Mar 1;73(5):443-53. doi: 10.1016/j.biopsych.2012.09.026. Epub 2012 Dec 4.

43.

Target-derived matricryptins organize cerebellar synapse formation through α3β1 integrins.

Su J, Stenbjorn RS, Gorse K, Su K, Hauser KF, Ricard-Blum S, Pihlajaniemi T, Fox MA.

Cell Rep. 2012 Aug 30;2(2):223-30. doi: 10.1016/j.celrep.2012.07.001. Epub 2012 Aug 9.

44.

HIV-1 alters neural and glial progenitor cell dynamics in the central nervous system: coordinated response to opiates during maturation.

Hahn YK, Podhaizer EM, Hauser KF, Knapp PE.

Glia. 2012 Dec;60(12):1871-87. doi: 10.1002/glia.22403. Epub 2012 Aug 2.

45.

Morphine efficacy is altered in conditional HIV-1 Tat transgenic mice.

Fitting S, Scoggins KL, Xu R, Dever SM, Knapp PE, Dewey WL, Hauser KF.

Eur J Pharmacol. 2012 Aug 15;689(1-3):96-103. doi: 10.1016/j.ejphar.2012.05.029. Epub 2012 May 30.

46.

Opiate drug use and the pathophysiology of neuroAIDS.

Hauser KF, Fitting S, Dever SM, Podhaizer EM, Knapp PE.

Curr HIV Res. 2012 Jul;10(5):435-52. Review.

47.

Differential expression and HIV-1 regulation of μ-opioid receptor splice variants across human central nervous system cell types.

Dever SM, Xu R, Fitting S, Knapp PE, Hauser KF.

J Neurovirol. 2012 Jun;18(3):181-90. doi: 10.1007/s13365-012-0096-z. Epub 2012 Apr 20.

48.

Lateralized response of dynorphin a peptide levels after traumatic brain injury.

Hussain ZM, Fitting S, Watanabe H, Usynin I, Yakovleva T, Knapp PE, Scheff SW, Hauser KF, Bakalkin G.

J Neurotrauma. 2012 Jun 10;29(9):1785-93. doi: 10.1089/neu.2011.2286. Epub 2012 May 21.

49.

Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at μ-opioid receptor-expressing glia.

Zou S, Fitting S, Hahn YK, Welch SP, El-Hage N, Hauser KF, Knapp PE.

Brain. 2011 Dec;134(Pt 12):3616-31. doi: 10.1093/brain/awr281. Epub 2011 Nov 18.

50.

Morphine and gp120 toxic interactions in striatal neurons are dependent on HIV-1 strain.

Podhaizer EM, Zou S, Fitting S, Samano KL, El-Hage N, Knapp PE, Hauser KF.

J Neuroimmune Pharmacol. 2012 Dec;7(4):877-91. doi: 10.1007/s11481-011-9326-z. Epub 2011 Nov 19.

Supplemental Content

Loading ...
Support Center